15-Year study launches to monitor safety of experimental TCR-T therapy

NCT ID NCT06976736

Recruiting now Knowledge-focused Sponsor: TScan Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 1,000 people who previously received an experimental cell therapy (TSC-100 or TSC-101) for blood cancers like leukemia. Researchers will track side effects and survival for up to 15 years to see if the treatment remains safe and effective over time. No new treatment is given; it is purely a monitoring study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TSC-100 and TSC-101 (TCR-T cell therapies)
What this could lead to: If successful, this study will confirm whether these TCR-T therapies are safe and help prevent cancer relapse over the long term.
What could go wrong: This is an observational follow-up, not a treatment trial. It cannot prove the therapy works, and long-term side effects may still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALL AML MDS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Mount Sinai
RECRUITING

New York, New York, 10029-6696, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.